Customer Logins

Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.

Customer Logins

My Logins

All Customer Logins
S&P Global S&P Global Marketplace
Explore S&P Global

  • S&P Global
  • S&P Dow Jones Indices
  • S&P Global Market Intelligence
  • S&P Global Mobility
  • S&P Global Commodity Insights
  • S&P Global Ratings
  • S&P Global Sustainable1
Close
Discover more about S&P Global’s offerings
Investor Relations
  • Investor Relations Overview
  • Investor Presentations
  • Investor Fact Book
  • News Releases
  • Quarterly Earnings
  • SEC Filings & Reports
  • Executive Committee
  • Corporate Governance
  • Merger Information
  • Stock & Dividends
  • Shareholder Services
  • Contact Investor Relations
Languages
  • English
  • 中文
  • 日本語
  • 한국어
  • Português
  • Español
  • ไทย
About
  • About Us
  • Contact Us
  • Email Subscription Center
  • Media Center
  • Glossary
Product Login
S&P Global S&P Global Market Intelligence Market Intelligence
  • Who We Serve
  • Solutions
  • News & Insights
  • Events
  • Product Login
  • Request Follow Up
  •  
    • Academia
    • Commercial Banking
    • Corporations
     
    • Government & Regulatory Agencies
    • Insurance
    • Investment & Global Banking
     
    • Investment Management
    • Private Equity
    • Professional Services
  • WORKFLOW SOLUTIONS
    • Capital Formation
    • Credit & Risk Solutions
    • Data & Distribution
    • Economics & Country Risk
    • Sustainability
    • Financial Technology
     
    • Issuer & IR Solutions
    • Lending Solutions
    • Post-Trade Processing
    • Private Markets
    • Risk, Compliance, & Reporting
    • Supply Chain
    PRODUCTS
    • S&P Capital IQ Pro
    • S&P Global Marketplace
    • China Credit Analytics
    • Climate Credit Analytics
    • Credit Analytics
    • RatingsDirect ®
    • RatingsXpress ®
    • 451 Research
    See More S&P Global Solutions
     
    • Capital Access
    • Corporate Actions
    • KY3P ®
    • EDM
    • PMI™
    • BD Corporate
    • Bond Pricing
    • ChartIQ
  • CONTENT
    • Latest Headlines
    • Special Features
    • Blog
    • Research
    • Videos
    • Infographics
    • Newsletters
    • Client Case Studies
    PODCASTS
    • The Decisive
    • IR in Focus
    • Masters of Risk
    • MediaTalk
    • Next in Tech
    • The Pipeline: M&A and IPO Insights
    • Private Markets 360°
    • Street Talk
    SEE ALL EPISODES
    SECTOR-SPECIFIC INSIGHTS
    • Differentiated Data
    • Banking & Insurance
    • Energy
    • Maritime, Trade, & Supply Chain
    • Metals & Mining
    • Technology, Media, & Telecoms
    • Investment Research
    • Sector Coverage
    • Consulting & Advisory Services
    More ways we can help
    NEWS & RESEARCH TOPICS
    • Credit & Risk
    • Economics & Country Risk
    • Financial Services
    • Generative AI
    • Maritime & Trade
    • M&A
    • Private Markets
    • Sustainability & Climate
    • Technology
    See More
    • All Events
    • In-Person
    • Webinars
    • Webinar Replays
    Featured Events
    Webinar2024 Trends in Data Visualization & Analytics
    • 10/17/2024
    • Live, Online
    • 11:00 AM - 12:00 PM EDT
    In PersonInteract New York 2024
    • 10/15/2024
    • Center415, 415 5th Avenue, New York, NY
    • 10:00 -17:00 CEST
    In PersonDatacenter and Energy Innovation Summit 2024
    • 10/30/2024
    • Convene Hamilton Square, 600 14th St NW, Washington, DC 20005, US
    • 7:30 AM - 5:00 PM ET
  • PLATFORMS
    • S&P Capital IQ Pro
    • S&P Capital IQ
    • S&P Global China Credit Analytics
    • S&P Global Marketplace
    OTHER PRODUCTS
    • Credit Analytics
    • Panjiva
    • Money Market Directories
     
    • Research Online
    • 451 Research
    • RatingsDirect®
    See All Product Logins
Same-Day Analysis

Malaysia pharmacists lobby against proposed Pharmacy Bill

Published: 27 May 2016

Malaysia's pharmacists continue to lobby against the country's proposed Pharmacy Bill, criticising the removal of the requirement that prescriptions be mandatory, according to Free Malaysia Today.



IHS Life Sciences perspective

Implications

The RUUF Focus Group (Rang Undang-Undang Farmasi: RUUF) petition has gathered over 11,000 signatures against the current draft of the Pharmacy Bill, which is expected to be tabled for Parliament this year.

Outlook

Debate is expected to continue between the ministry of health – which continues to argue that the country is "not ready" for dispensing separation – and pharmacists, who argue that Malaysia must bring its pharmaceutical regulations in line with international standards.

The RUUF Focus Group (Rang Undang-Undang Farmasi: RUUF) has begun an online petition against the bill that has gathered over 11,000 signatures (source: ipetitions.com), with the group aiming to collect 20,000 signatures. The Pharmacy Bill is expected to be tabled for Parliament this year.

Pharmacists argue that the removal of the requirement for mandatory prescriptions endangers patient safety, forcing patients to assume the responsibility of requesting prescriptions themselves and creating the possibility of being denied prescriptions by doctors. In response, Malaysia's Director General of Health, Datuk Dr Noor Hisham Abdullah, was quoted as stating that patients had the right to complain in response to physician-mishandling of prescriptions.

According to the source, pharmacists argue that as numerous pharmacies are not permitted to dispense medicines without a valid prescription, the patient would be forced to procure medication from doctors, which may prove more expensive. There is also a potential risk for doctors to abuse the system, forcing patients to purchase repeat prescriptions – a particular risk for elderly patients taking several medications. In addition, mandatory prescriptions are already a widespread practice among Malaysia's private hospitals, meeting international standards.

Pharmacists are also campaigning against three additional provisions of the Pharmacy Bill: allowing pharmaceutical compounding to be carried out by non-pharmacists; allowing psychotropic medicines to be dispensed by prescribers; and allowing pharmaceutical technology to be supervised by non-pharmacists.

The petition by the RUUF Focus Group comes after months of lobbying around the issue of dispensing separation (DS) in Malaysia (see Malaysia: 26 May 2016: Pharmacists should control drug dispensing in Malaysia, say experts).

Outlook and implications

The issue of dispensing separation has been hotly debated in Malaysia, with the Ministry of Health (MoH) arguing that the country is "not ready" for such a move. Pharmacists have strongly criticised this view, arguing that Malaysia is set to attain developed-nation status in 2020, and should bring its pharmaceutical regulations increasingly in line with international standards. The MoH has responded by highlighting the country's inadequate number of after-hours pharmacies, which would potentially limit patient access to (emergency) treatment. In addition, the MoH has pointed to what it regards as a lack of adequate pharmacist training and ability to competently advise patients on their medication.

While the introduction of DS in Malaysia is expected to boost the pharmaceutical industry by increasing the number of sources for medication-dispensing – given that pharmacists can typically dispense a wider range of drugs than private clinics – DS may also lead to a lowering of drug prices, alongside potentially higher consultation fees (see Malaysia: 18 February 2015: Malaysia's MoH considers new pharmacy dispensing system to lower prices). Malaysia currently lacks a formal drug-pricing system, a situation that has resulted in chronically high drug prices.

{"items" : [ {"name":"share","enabled":true,"desc":"<strong>Share</strong>","mobdesc":"Share","options":[ {"name":"facebook","url":"https://www.facebook.com/sharer.php?u=http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fID%3d10659114530","enabled":true},{"name":"twitter","url":"https://twitter.com/intent/tweet?url=http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fID%3d10659114530&text=Malaysia+pharmacists+lobby+against+proposed+Pharmacy+Bill","enabled":true},{"name":"linkedin","url":"https://www.linkedin.com/sharing/share-offsite/?url=http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fID%3d10659114530","enabled":true},{"name":"email","url":"?subject=Malaysia pharmacists lobby against proposed Pharmacy Bill&body=http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fID%3d10659114530","enabled":true},{"name":"whatsapp","url":"https://api.whatsapp.com/send?text=Malaysia+pharmacists+lobby+against+proposed+Pharmacy+Bill http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fID%3d10659114530","enabled":true}]}, {"name":"rtt","enabled":true,"mobdesc":"Top"} ]}
Filter Sort
  • About S&P Global Market Intelligence
  • Quality Program
  • Email Subscription Center
  • Media Center
  • Our Values
  • Investor Relations
  • Contact Customer Care & Sales
  • Careers
  • Our History
  • News Releases
  • Support by Division
  • Corporate Responsibility
  • Ventures
  • Quarterly Earnings
  • Report an Ethics Concern
  • Leadership
  • Press
  • SEC Filings & Reports
  • Office Locations
  • IOSCO ESG Rating & Data Product Statements
  • © 2025 S&P Global
  • Terms of Use
  • Cookie Notice
  • Privacy Policy
  • Disclosures
  • Do Not Sell My Personal Information